RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Penn-Nicholson, Adam; Mbandi, Stanley Kimbung; Thompson, Ethan; Mendelsohn, Simon C.; Suliman, Sara; Chegou, Novel N.; Malherbe, Stephanus T.; Darboe, Fatoumatta; Erasmus, Mzwandile; Hanekom, Willem A.; Bilek, Nicole; Fisher, Michelle; Kaufmann, Stefan H. E.; Winter, Jill; Murphy, Melissa; Wood, Robin; Morrow, Carl; Van Rhijn, Ildiko; Moody, Branch; Murray, Megan; Andrade, Bruno de Bezerril; Sterling, Timothy R.; Sutherland, Jayne; Naidoo, Kogieleum; Padayatchi, Nesri; Walzl, Gerhard; Hatherill, Mark; Zak, Daniel; Scriba, Thomas J.

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Detalhes bibliográficos
Autor(a) principal:	Penn-Nicholson, Adam
Data de Publicação:	2020
Outros Autores:	Mbandi, Stanley Kimbung, Thompson, Ethan, Mendelsohn, Simon C., Suliman, Sara, Chegou, Novel N., Malherbe, Stephanus T., Darboe, Fatoumatta, Erasmus, Mzwandile, Hanekom, Willem A., Bilek, Nicole, Fisher, Michelle, Kaufmann, Stefan H. E., Winter, Jill, Murphy, Melissa, Wood, Robin, Morrow, Carl, Van Rhijn, Ildiko, Moody, Branch, Murray, Megan, Andrade, Bruno de Bezerril, Sterling, Timothy R., Sutherland, Jayne, Naidoo, Kogieleum, Padayatchi, Nesri, Walzl, Gerhard, Hatherill, Mark, Zak, Daniel, Scriba, Thomas J.
Tipo de documento:	Artigo
Idioma:	eng
Título da fonte:	Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo:	https://www.arca.fiocruz.br/handle/icict/42435
Resumo:	Valeria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.

Metadados do item

id	CRUZ_9600aec3dd9f65a65410af8e7f02f941
oai_identifier_str	oai:www.arca.fiocruz.br:icict/42435
network_acronym_str	CRUZ
network_name_str	Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str	2135
spelling	Penn-Nicholson, AdamMbandi, Stanley KimbungThompson, EthanMendelsohn, Simon C.Suliman, SaraChegou, Novel N.Malherbe, Stephanus T.Darboe, FatoumattaErasmus, MzwandileHanekom, Willem A.Bilek, NicoleFisher, MichelleKaufmann, Stefan H. E.Winter, JillMurphy, MelissaWood, RobinMorrow, CarlVan Rhijn, IldikoMoody, BranchMurray, MeganAndrade, Bruno de BezerrilSterling, Timothy R.Sutherland, JayneNaidoo, KogieleumPadayatchi, NesriWalzl, GerhardHatherill, MarkZak, DanielScriba, Thomas J.2020-07-28T19:58:50Z2020-07-28T19:58:50Z2020PENN-NICHOLSON, Adam et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, v. 10, n. 1, p. 1-21, 2020.2045-2322https://www.arca.fiocruz.br/handle/icict/4243510.1038/s41598-020-65043-8Valeria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.Center for Infectious Disease Research. Seattle, WA, USA.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa / Harvard Medical School. Division of Rheumatology, Immunity and Inflammation. Brigham and Women’s Hospital. Boston, USA.Stellenbosch University. Faculty of Medicine and Health Sciences. Division of Molecular Biology and Human Genetics. South African Medical Research Council Centre for Tuberculosis Research. Cape Town, South Africa.Stellenbosch University. Faculty of Medicine and Health Sciences. Division of Molecular Biology and Human Genetics. South African Medical Research Council Centre for Tuberculosis Research. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.Max Planck Institute for Infection Biology. Berlin, Germany / Hagler Institute for Advanced Study at Texas A&M University. College Station, TX, USA.Catalysis Foundation for Health. San Ramon, CA, USA.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.University of Cape Town. Desmond Tutu HIV Centre, and Institute of Infectious Disease and Molecular Medicine. Cape Town, South Africa.University of Cape Town. Desmond Tutu HIV Centre, and Institute of Infectious Disease and Molecular Medicine. Cape Town, South Africa.Harvard Medical School. Division of Rheumatology, Immunity and Inflammation. Brigham and Women’s Hospital. Boston, USA.Harvard Medical School. Division of Rheumatology, Immunity and Inflammation. Brigham and Women’s Hospital. Boston, USA.Harvard Medical School. Department of Global Health and Social Medicine, and Division of Global Health Equity. Brigham and Women’s Hospital. Boston, MA, USA.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Vanderbilt University School of Medicine. Department of Medicine. Division of Infectious Diseases. Nashville, USA.Medical Research Council Unit. Vaccines and Immunity. Fajara, The Gambia.Centre for the AIDS Programme of Research in Africa. Durban, South Africa / South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit. Durban, South Africa.Centre for the AIDS Programme of Research in Africa. Durban, South Africa / South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit. Durban, South Africa.Stellenbosch University. Faculty of Medicine and Health Sciences. Division of Molecular Biology and Human Genetics. South African Medical Research Council Centre for Tuberculosis Research. Cape Town, South Africa.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.Center for Infectious Disease Research. Seattle, WA, USA.University of Cape Town. Department of Pathology. Institute of Infectious Disease and Molecular Medicine and Division of Immunology. South African Tuberculosis Vaccine Initiative. Cape Town, South Africa.Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with lung immunopathology activity, measured by positron emission tomography, and tracked treatment response, demonstrating utility as treatment response biomarker, while predicting treatment failure prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field studies.engNature ResearchRISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleDiagnostic markersPrognostic markersTuberculosisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://www.arca.fiocruz.br/bitstream/icict/42435/1/license.txt586c046dcfeef936e32f0323bb9a47c0MD51ORIGINALRISK6_Valeria_Rolla_etal_INI_2020.pdfRISK6_Valeria_Rolla_etal_INI_2020.pdfapplication/pdf6233955https://www.arca.fiocruz.br/bitstream/icict/42435/2/RISK6_Valeria_Rolla_etal_INI_2020.pdf091660ee01efa9d259ca71c17d524f3aMD52TEXTRISK6_Valeria_Rolla_etal_INI_2020.pdf.txtRISK6_Valeria_Rolla_etal_INI_2020.pdf.txtExtracted texttext/plain103734https://www.arca.fiocruz.br/bitstream/icict/42435/3/RISK6_Valeria_Rolla_etal_INI_2020.pdf.txtbf5d6a420b2ef32837e044e540fb02eeMD53icict/424352021-10-21 12:37:21.253oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-10-21T15:37:21Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
title	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
spellingShingle	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response Penn-Nicholson, Adam Diagnostic markers Prognostic markers Tuberculosis
title_short	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
title_full	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
title_fullStr	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
title_full_unstemmed	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
title_sort	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
author	Penn-Nicholson, Adam
author_facet	Penn-Nicholson, Adam Mbandi, Stanley Kimbung Thompson, Ethan Mendelsohn, Simon C. Suliman, Sara Chegou, Novel N. Malherbe, Stephanus T. Darboe, Fatoumatta Erasmus, Mzwandile Hanekom, Willem A. Bilek, Nicole Fisher, Michelle Kaufmann, Stefan H. E. Winter, Jill Murphy, Melissa Wood, Robin Morrow, Carl Van Rhijn, Ildiko Moody, Branch Murray, Megan Andrade, Bruno de Bezerril Sterling, Timothy R. Sutherland, Jayne Naidoo, Kogieleum Padayatchi, Nesri Walzl, Gerhard Hatherill, Mark Zak, Daniel Scriba, Thomas J.
author_role	author
author2	Mbandi, Stanley Kimbung Thompson, Ethan Mendelsohn, Simon C. Suliman, Sara Chegou, Novel N. Malherbe, Stephanus T. Darboe, Fatoumatta Erasmus, Mzwandile Hanekom, Willem A. Bilek, Nicole Fisher, Michelle Kaufmann, Stefan H. E. Winter, Jill Murphy, Melissa Wood, Robin Morrow, Carl Van Rhijn, Ildiko Moody, Branch Murray, Megan Andrade, Bruno de Bezerril Sterling, Timothy R. Sutherland, Jayne Naidoo, Kogieleum Padayatchi, Nesri Walzl, Gerhard Hatherill, Mark Zak, Daniel Scriba, Thomas J.
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.author.fl_str_mv	Penn-Nicholson, Adam Mbandi, Stanley Kimbung Thompson, Ethan Mendelsohn, Simon C. Suliman, Sara Chegou, Novel N. Malherbe, Stephanus T. Darboe, Fatoumatta Erasmus, Mzwandile Hanekom, Willem A. Bilek, Nicole Fisher, Michelle Kaufmann, Stefan H. E. Winter, Jill Murphy, Melissa Wood, Robin Morrow, Carl Van Rhijn, Ildiko Moody, Branch Murray, Megan Andrade, Bruno de Bezerril Sterling, Timothy R. Sutherland, Jayne Naidoo, Kogieleum Padayatchi, Nesri Walzl, Gerhard Hatherill, Mark Zak, Daniel Scriba, Thomas J.
dc.subject.en.pt_BR.fl_str_mv	Diagnostic markers Prognostic markers Tuberculosis
topic	Diagnostic markers Prognostic markers Tuberculosis
description	Valeria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento.
publishDate	2020
dc.date.accessioned.fl_str_mv	2020-07-28T19:58:50Z
dc.date.available.fl_str_mv	2020-07-28T19:58:50Z
dc.date.issued.fl_str_mv	2020
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.citation.fl_str_mv	PENN-NICHOLSON, Adam et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, v. 10, n. 1, p. 1-21, 2020.
dc.identifier.uri.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/42435
dc.identifier.issn.pt_BR.fl_str_mv	2045-2322
dc.identifier.doi.none.fl_str_mv	10.1038/s41598-020-65043-8
identifier_str_mv	PENN-NICHOLSON, Adam et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, v. 10, n. 1, p. 1-21, 2020. 2045-2322 10.1038/s41598-020-65043-8
url	https://www.arca.fiocruz.br/handle/icict/42435
dc.language.iso.fl_str_mv	eng
language	eng
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Nature Research
publisher.none.fl_str_mv	Nature Research
dc.source.none.fl_str_mv	reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ
instname_str	Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str	FIOCRUZ
institution	FIOCRUZ
reponame_str	Repositório Institucional da FIOCRUZ (ARCA)
collection	Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv	https://www.arca.fiocruz.br/bitstream/icict/42435/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/42435/2/RISK6_Valeria_Rolla_etal_INI_2020.pdf https://www.arca.fiocruz.br/bitstream/icict/42435/3/RISK6_Valeria_Rolla_etal_INI_2020.pdf.txt
bitstream.checksum.fl_str_mv	586c046dcfeef936e32f0323bb9a47c0 091660ee01efa9d259ca71c17d524f3a bf5d6a420b2ef32837e044e540fb02ee
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv	repositorio.arca@fiocruz.br
_version_	1798324961661681664

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Registros relacionados